Skip to main content

Vera Therapeutics, Inc.

corporate_fare Company Profile

Vera Therapeutics, Inc.

VERA·NASDAQ·Life Sciences·CIK 0001831828

Vera Therapeutics, Inc. is a late clinical-stage biotechnology company focused on developing and commercializing treatments for serious immunological diseases. The company's primary product candidate is atacicept, which is being developed for immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. Atacicept is a native human TACI-Fc fusion protein that binds to both B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) cytokines, and it is designed for self-administration subcutaneously at home. Vera Therapeutics is conducting ORIGIN 3, a pivotal Phase 3 trial for atacicept 150 mg in IgAN. This trial met its primary efficacy endpoint, demonstrating a 46% reduction from baseline in proteinuria, measured by 24-hour urine protein-to-creatinine ratio (UPCR), at week 36. This represented a statistically significant and clinically meaningful 42% reduction in UPCR compared to placebo (p<0.0001). The incidence of adverse events was generally balanced between the atacicept and placebo groups, with fewer serious adverse events reported with atacicept (n=1 [0.5%]) than placebo (n=11 [5%]), no safety signals indicating immunosuppression, and no deaths in either treatment group. In November 2025, the company submitted a Biologics License Application (BLA) for atacicept for the treatment of adults with IgAN to the U.S. Food and Drug Administration (FDA) through the Accelerated Approval Program. On January 7, 2026, the FDA granted priority review to this application and set a Prescription Drug User Fee Act (PDUFA) target action date of July 7, 2026. The ORIGIN Phase 2b clinical trial, which evaluated atacicept in 116 participants with IgAN, reported positive results at 24 weeks in January 2023, 36 weeks in June 2023, and 96 weeks in October 2024. The ORIGIN 3 key secondary endpoint to support full approval is estimated glomerular filtration rate (eGFR) at 104 weeks, with results expected in 2027.

Vera Therapeutics, Inc. (NASDAQ:VERA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for VERA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 8/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for VERA spans 10-Q, 8-K, 144, DEF 14A.

Recent high-impact activity:

  • Vera 10-Q: First TRUTAKNA Revenue $10.3M, Cash $384M, Q4 Charge of Up to $14.6M
  • Vera Q3: First TRUTAKNA Revenue of $10.3M, Net Loss Narrows to $93.7M
  • Vera Therapeutics Q3 Loss Narrower Than Expected at $93.7M
  • TRUTAKNA Hits All Endpoints in ORIGIN 3 Final Analysis — 76% Risk Reduction in Kidney Disease Progression
  • TRUTAKNA Cuts Kidney Disease Progression by 76% in Phase 3, Setting Stage for Full Approval

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$299.62M
Diluted EPS
-$4.66
Op. Cash Flow
-$241.1M
Free Cash Flow
-$241.73M
Operating Income
-$315.47M
Cash & Equivalents
$354.73M
Total Debt
$74.84M
Debt / Equity
0.12×
Shares Outstanding
64.23M sh
Source: 10-K · filed 2026-02-26 · accession 0001193125-26-077442

Short Interest & Short Volume

8.47 days to cover

FINRA reported short interest of 12,141,556 shares in VERA as of the October 30, 2026 settlement, a 10.6% decrease from the prior period — about 8.5 days to cover at its recent average daily volume. On November 20, 2026, 63.9% of VERA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)12,141,556 shares as of October 30, 2026
Change vs prior period▼ 10.6%
Days to cover8.47 at avg daily volume of 1,433,704
Daily short volume (FINRA facilities)63.9% of 411,718 shares on November 20, 2026
5-day average short volume56.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with V →
$24.88 -2.24% today
52-week range · as of 2026-11-05 $23.05 – $56.05
Market cap
$1.84B
Volume
1.4M (0.9× avg)
3-mo avg 1.5M
Live data · 2026-11-22 06:27 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed VERA - Latest Insights

VERA
Nov 05, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $29.53
Real-time Price: $24.88 info
Change: -$4.65 (-16%) info
Market Cap: $1.84B info
VERA
Nov 05, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $31.07
Real-time Price: $24.88 info
Change: -$6.19 (-20%) info
Market Cap: $1.84B info
VERA
Nov 05, 2026, 4:02 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $30.98
Real-time Price: $24.88 info
Change: -$6.10 (-20%) info
Market Cap: $1.84B info
VERA
Sep 15, 2026, 6:45 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $38.64
Real-time Price: $24.88 info
Change: -$13.76 (-36%) info
Market Cap: $1.84B info
VERA
Sep 15, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $37.69
Real-time Price: $24.88 info
Change: -$12.81 (-34%) info
Market Cap: $1.84B info
VERA
Aug 10, 2026, 5:07 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $31.50
Real-time Price: $24.88 info
Change: -$6.62 (-21%) info
Market Cap: $1.84B info
VERA
Aug 10, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $31.58
Real-time Price: $24.88 info
Change: -$6.70 (-21%) info
Market Cap: $1.84B info
VERA
Jul 07, 2026, 12:45 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $42.10
Real-time Price: $24.88 info
Change: -$17.22 (-41%) info
Market Cap: $1.84B info
VERA
Jul 07, 2026, 12:37 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $42.43
Real-time Price: $24.88 info
Change: -$17.55 (-41%) info
Market Cap: $1.84B info
VERA
Jun 23, 2026, 4:29 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $38.20
Real-time Price: $24.88 info
Change: -$13.32 (-35%) info
Market Cap: $1.84B info
VERA
Jun 02, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $34.31
Real-time Price: $24.88 info
Change: -$9.43 (-27%) info
Market Cap: $1.84B info
VERA
Jun 02, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $34.31
Real-time Price: $24.88 info
Change: -$9.43 (-27%) info
Market Cap: $1.84B info
VERA
May 07, 2026, 4:33 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $35.88
Real-time Price: $24.88 info
Change: -$11.00 (-31%) info
Market Cap: $1.84B info
VERA
May 07, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $36.50
Real-time Price: $24.88 info
Change: -$11.62 (-32%) info
Market Cap: $1.84B info
VERA
Apr 09, 2026, 4:05 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $40.91
Real-time Price: $24.88 info
Change: -$16.03 (-39%) info
Market Cap: $1.84B info
VERA
Mar 05, 2026, 6:11 AM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $39.89
Real-time Price: $24.88 info
Change: -$15.01 (-38%) info
Market Cap: $1.84B info
VERA
Feb 26, 2026, 5:25 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $42.12
Real-time Price: $24.88 info
Change: -$17.24 (-41%) info
Market Cap: $1.84B info
VERA
Feb 26, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $41.68
Real-time Price: $24.88 info
Change: -$16.80 (-40%) info
Market Cap: $1.84B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets